Freeline Therapeutics Holdings plc Net Income | FRLN

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Freeline Therapeutics Holdings plc

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-89 M	-140 M	-96.3 M	-53.9 M	-33.3 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-33.3 M	-140 M	-82.6 M

Quarterly Net Income Freeline Therapeutics Holdings plc

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-26.9 M	-14.8 M	1.17 M	-89 M	-66 M	-51.1 M	-26.7 M	-140 M	-106 M	-74.8 M	-34.9 M	-96.3 M	-	-33.3 M	-16.7 M	-53.9 M	-	-24.7 M	-	-33.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.17 M	-140 M	-52.2 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
AnaptysBio ANAB	131 M	$ 51.7	1.83 %	$ 1.5 B	USA
Allakos ALLK	-116 M	-	-	$ 28.6 M	USA
Bicycle Therapeutics plc BCYC	-219 M	$ 3.73	3.61 %	$ 258 M	Britain
Black Diamond Therapeutics BDTX	22.4 B	$ 1.89	0.53 %	$ 107 M	USA
Clovis Oncology CLVS	-64.4 M	-	-7.23 %	$ 13 M	USA
Concert Pharmaceuticals CNCE	-80.1 M	-	-	$ 401 M	USA
Rezolute RZLT	-77.6 M	$ 3.94	1.87 %	$ 299 M	USA
Evelo Biosciences EVLO	-115 M	-	-14.46 %	$ 27.9 M	USA
BioLineRx Ltd. BLRX	-2.03 M	$ 2.52	1.17 %	$ 6.21 B	Israel
BioMarin Pharmaceutical BMRN	349 M	$ 61.35	0.06 %	$ 11.8 B	USA
Benitec Biopharma BNTC	-45.5 M	$ 9.64	0.46 %	$ 449 M	USA
BioNTech SE BNTX	-1.14 B	$ 99.26	0.81 %	$ 24 B	Germany
Genocea Biosciences GNCA	-33.2 M	-	-15.0 %	$ 3.04 M	USA
Burford Capital Limited BUR	62.6 M	$ 3.63	3.93 %	$ 795 M	Britain
Amryt Pharma plc AMYT	1 M	-	-	$ 621 M	Britain
G1 Therapeutics GTHX	-48 M	-	-	$ 370 M	USA
Can-Fite BioPharma Ltd. CANF	-9.83 M	$ 2.17	0.46 %	$ 3.57 M	Israel
Catalyst Biosciences CBIO	9.88 M	$ 14.24	0.35 %	$ 1.27 B	USA
C4 Therapeutics CCCC	-105 M	$ 3.03	0.3 %	$ 251 M	USA
Codexis CDXS	-44 M	$ 1.37	1.45 %	$ 119 M	USA
Cerus Corporation CERS	-15.6 M	$ 2.61	0.38 %	$ 497 M	USA
AbbVie ABBV	1.82 B	$ 265.12	0.09 %	$ 469 B	USA
Humanigen HGEN	-70.7 M	-	-81.12 %	$ 4.28 M	USA
Coherus BioSciences CHRS	168 M	$ 1.17	1.48 %	$ 137 M	USA
AbCellera Biologics ABCL	-146 M	$ 12.65	2.76 %	$ 3.78 B	Canada
Abeona Therapeutics ABEO	-71.2 M	$ 5.43	2.65 %	$ 288 M	USA
Celldex Therapeutics CLDX	-259 M	$ 31.48	1.16 %	$ 2.09 B	USA
CollPlant Biotechnologies Ltd. CLGN	-11.5 M	$ 4.12	1.98 %	$ 50.3 M	Israel
Фармсинтез LIFE	-525 M	-	-	-	Russia
Cellectar Biosciences CLRB	-21.8 M	$ 2.08	0.48 %	$ 5.43 M	USA
IGM Biosciences IGMS	-196 M	-	-	$ 76.9 M	USA
IMV IMV	-38 M	-	-	$ 13.1 M	Canada
Kinnate Biopharma KNTE	-113 M	-	-	$ 123 M	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Karuna Therapeutics KRTX	-434 M	-	-	$ 12.2 B	USA
Cocrystal Pharma COCP	-8.83 M	$ 1.15	1.67 %	$ 13 M	USA
Crinetics Pharmaceuticals CRNX	-465 M	$ 84.95	0.13 %	$ 7.99 B	USA
Collegium Pharmaceutical COLL	63 M	$ 22.64	0.85 %	$ 717 M	USA
Corcept Therapeutics Incorporated CORT	99.7 M	$ 118.51	4.93 %	$ 12.3 B	USA
Chimerix CMRX	-88.4 M	-	-	$ 756 M	USA
Corbus Pharmaceuticals Holdings CRBP	-78.5 M	$ 7.45	0.19 %	$ 99.2 M	USA
Curis CRIS	-7.58 M	$ 0.88	0.85 %	$ 11.6 M	USA
CorMedix CRMD	163 M	$ 7.77	1.04 %	$ 560 K	USA
CRISPR Therapeutics AG CRSP	-582 M	$ 55.7	0.23 %	$ 5.01 B	Schweiz
Corvus Pharmaceuticals CRVS	-15.3 M	$ 11.8	8.21 %	$ 932 M	USA
Champions Oncology CSBR	-1.18 M	$ 4.95	0.38 %	$ 68.5 M	USA
Arbutus Biopharma Corporation ABUS	-33.5 M	$ 4.88	0.62 %	$ 935 M	Canada
Cue Biopharma CUE	-26.6 M	$ 32.85	3.6 %	$ 3.11 B	USA
CEL-SCI Corporation CVM	-25.4 M	$ 1.72	2.38 %	$ 13.8 M	USA